If last week had a unifying theme, it was repricing. Strategic buyers put fresh numbers on imaging components and cardiac monitoring. Anchor investors recalculated what confidence is worth. And the FDA — twice in one week — recalculated what market entry should cost, holding user fees roughly flat for U.S. firms and proposing to drop an entire imaging category out of PMA territory. The price of admission to this industry is being renegotiated in real time, and not always upward.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🩻 Teledyne to acquire Varex Imaging for $1.1B
Teledyne is buying X-ray component maker Varex Imaging for $18.90 per share in cash — roughly $1.1 billion — folding Varex’s X-ray tubes, flat-panel and photon-counting detectors into its imaging portfolio, with close expected in early 2027. After a summer of private equity buying up the supply layer, this is a strategic buyer doing the same math: the components underneath the imaging systems are worth owning outright.
MPO Magazine
2. 🏛️ Industry backs MDUFA VI as patient groups push for postmarket teeth
At the FDA’s public meeting on the MDUFA VI draft agreement, industry voiced broad support for a deal that keeps user fees roughly flat — or lower — for U.S. firms, shifts higher establishment fees onto overseas companies, and swaps MDUFA V’s hiring targets for regular CDRH headcount reporting. Comments run through year-end with the package headed to Congress in January; if the structure holds, your FY2028–2032 submission budget just got materially more predictable.
MedTech Dive
3. 🧭 Most device companies don't fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you're strongest, where you're exposed, and what to fix first. If you want help closing a gap, it'll point you to the right starting place.
Sponsored by RŌG Health
4. 📲 Abbott and Google pair Lingo glucose data with AI coaching
Abbott’s over-the-counter Lingo CGM will integrate with the Google Health app under a multiyear partnership, feeding glucose trends into Google’s Gemini-powered Health Coach and anchoring one of the largest real-world metabolic health studies attempted, with app integrations rolling out later this year. The consumer-health land grab now runs through distribution partners, and Abbott just secured the biggest one available.
Fierce Biotech
5. 🫀 iRhythm buys VitalConnect for $287.5M to expand cardiac monitoring reach
iRhythm is acquiring wearable biosensor maker VitalConnect — $237.5 million in cash plus $50 million in stock — adding the VitalPatch and mobile cardiac telemetry capabilities that extend the Zio platform from ambulatory arrhythmia detection into inpatient and hospital-to-home monitoring, with close expected by year-end. A category leader paying up to close its own portfolio gap before someone else does.
Cardiovascular Business
6. 🎗️ FDA proposes down-classifying digital breast tomosynthesis from Class III to Class II
The FDA published a proposed order moving DBT systems from Class III premarket approval to Class II with special controls — performance testing, software validation, clinical image evaluation — clearing 510(k) as the path for a technology that’s carried the PMA burden since 2011, with comments due October 9. Fifteen years of PMA data bought the whole category a cheaper regulatory ticket; worth watching which device type the agency down-classifies next.
Federal Register
7. 🤝 Philips lifts Exor’s ownership cap to 22% in updated agreement
Philips will let its largest shareholder, the Agnelli family’s Exor, raise its stake from the previous 20% cap to 22% — with room to go higher pending supervisory board approval — while governance terms stay unchanged. Exor bought in at 15% during the depths of the Respironics fallout; deepening the position now is a bet that the 2026–2028 turnaround plan is real.
MassDevice
8. 🏥 GE HealthCare weighs sale of $3B Patient Care Solutions business
GE HealthCare is reviewing strategic options — including a sale — for Patient Care Solutions, its patient monitoring, diagnostic cardiology, maternal-infant care, and anesthesia unit, which posted a 13.5% revenue decline and negative margins last quarter while representing about 15% of company revenue. Pair this with item #5 and a picture forms: monitoring assets are changing hands, and the question is who’s a natural owner.
MD+DI
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.